Search research articles
Contact Us
Filters
Showing results (381-390 of 509) with videos related to
Page
of 51
Sort By:
JAMA Network Open
|
April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations
Philip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the science
Rachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde, Marina Pulido, Isabelle Ray-Coquard, et al.
Nature Medicine
|
April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial
Olivier Trédan, Damien Pouessel, Nicolas Penel, et al.
Bulletin Du Cancer
|
November 4, 2005
[Recommendations for the management of GIST patients]
Jean-Yves Blay, Bruno Landi, Sylvie Bonvalot, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Gynecologic Oncology
|
December 13, 2024
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Henri Azaïs, Camille Brochard, Valérie Taly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Page
of 51
Search research articles
Search
Showing results (381-390 of 509) with videos related to
Sort By:
Page
of 51
JAMA Network Open
|
April 9, 2024
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations
Philip C Schouten, Sandra Schmidt, Kerstin Becker, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
August 17, 2023
Low-grade serous ovarian cancer: expert consensus report on the state of the science
Rachel N Grisham, Brian M Slomovitz, Nicole Andrews, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
The Lancet. Oncology
|
July 24, 2019
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde, Marina Pulido, Isabelle Ray-Coquard, et al.
Nature Medicine
|
April 8, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial
Olivier Trédan, Damien Pouessel, Nicolas Penel, et al.
Bulletin Du Cancer
|
November 4, 2005
[Recommendations for the management of GIST patients]
Jean-Yves Blay, Bruno Landi, Sylvie Bonvalot, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Gynecologic Oncology
|
December 13, 2024
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Henri Azaïs, Camille Brochard, Valérie Taly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 14, 2023
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, et al.
Page
of 51